Treating pulmonary hypertension depends on what’s causing it, but the core goal is always the same: reduce the abnormally high pressure in your lung arteries, ease symptoms like breathlessness and fatigue, and slow the disease’s progression. There is no single cure, but a combination of medications, lifestyle adjustments, and in some cases surgery can significantly improve quality of life and survival. Five-year survival rates now reach roughly 82% for many patients on modern therapy, a substantial improvement over earlier decades.
Why the Cause Determines the Treatment
Pulmonary hypertension falls into five broad clinical categories based on what’s driving the elevated pressure: pulmonary arterial hypertension (PAH), left heart disease, lung diseases or chronic low oxygen, blood clot obstructions in the pulmonary arteries, and a mixed category that includes conditions like sickle cell disease and sarcoidosis. This classification matters because treatments that work well for one group can be ineffective or even harmful in another. PAH, for example, has a large and growing toolkit of targeted medications, while pulmonary hypertension caused by left heart disease is primarily managed by treating the underlying heart condition.
Before starting any treatment plan, doctors typically run imaging, blood tests, and right heart catheterization to identify which group you fall into and how severe the pressure elevation is. That diagnostic step shapes everything that follows.
Medications That Open the Blood Vessels
The majority of PAH-specific drugs work by relaxing and widening the narrowed arteries in the lungs. They target three distinct biological pathways, and many patients end up on a combination of two or three drugs hitting different pathways at once. That shift toward combination therapy has been one of the biggest drivers of improved survival in recent years.
Drugs That Boost Nitric Oxide Signaling
One class of medications works by amplifying the effects of nitric oxide, a natural molecule your body uses to relax blood vessel walls. These drugs block an enzyme that breaks down the chemical messenger responsible for that relaxation. Two are commonly used: sildenafil (taken three times daily) and tadalafil (taken once daily). Side effects can include headache, flushing, and digestive upset, but these medications are generally well tolerated and have become a cornerstone of PAH treatment.
A separate drug in this same pathway, riociguat, works slightly differently by directly stimulating the production of the relaxation signal rather than just preventing its breakdown. It cannot be combined with sildenafil or tadalafil.
Endothelin Blockers
Endothelin is a protein your body produces that powerfully constricts blood vessels. In PAH, there’s too much of it. Three medications block its effects: bosentan, ambrisentan, and macitentan. All are taken as pills. Common side effects include swelling in the legs, flushing, and headache. Liver enzyme changes can occur, particularly with bosentan, so regular blood monitoring is part of the treatment routine. All three carry a risk of birth defects and require reliable contraception for women of childbearing age.
Prostacyclin Therapy
Prostacyclin is another natural substance that relaxes blood vessels and prevents blood cells from clumping. For patients with more advanced disease, medications that mimic prostacyclin can be highly effective, though they come with more complex delivery methods.
Epoprostenol is the oldest and most potent option. It has an extremely short half-life of just three to five minutes, which means it must be delivered continuously through an IV pump connected to a surgically placed catheter. That setup is demanding but can be life-changing for people with severe symptoms. Treprostinil offers more flexibility: it’s available as a continuous IV or subcutaneous infusion, an inhaled form, and an oral tablet. The subcutaneous pump eliminates the need for a permanent central IV line, making outpatient life more manageable. Iloprost is inhaled and has a longer half-life of 20 to 30 minutes, allowing doses every two to four hours rather than continuous delivery.
A newer oral option, selexipag, activates the same pathway without being a direct prostacyclin copy, giving patients a pill-based alternative.
A Newer Class of Treatment
Sotatercept represents a fundamentally different approach. Rather than just relaxing blood vessels, it targets the abnormal cell growth that thickens and stiffens the walls of lung arteries over time. In clinical trials, patients receiving the higher dose saw a 34% reduction in pulmonary vascular resistance from baseline and walked about 41 meters farther in a six-minute walk test compared to those on placebo. Those are meaningful improvements on top of existing background therapy. Sotatercept is given as a subcutaneous injection every three weeks and became the first drug in its class approved for PAH.
Surgery for Blood Clot-Related Disease
When pulmonary hypertension is caused by chronic blood clots that have organized and scarred inside the lung arteries, a condition called chronic thromboembolic pulmonary hypertension (CTEPH), surgery can potentially be curative. The procedure, called pulmonary endarterectomy, involves opening the pulmonary arteries and physically removing the clot material from the vessel walls.
Not everyone with CTEPH qualifies. Clots need to be located in the main, lobar, or segmental arteries where a surgeon can reach them. Disease that starts in smaller subsegmental branches is far more challenging and may not be operable. Candidates must also have been on blood thinners for at least three months before the diagnosis is confirmed. For patients who aren’t surgical candidates, balloon pulmonary angioplasty (a catheter-based technique) and the medication riociguat are alternatives.
In the most severe cases of any form of pulmonary hypertension that doesn’t respond to medical therapy, lung transplantation remains an option, though it carries significant risks and a limited donor supply.
Oxygen Therapy
Low oxygen levels are both a cause and a consequence of pulmonary hypertension. When blood oxygen saturation drops to 88% or below (or arterial oxygen pressure falls to 55 mmHg or less), supplemental oxygen is typically prescribed for long-term use. Even at slightly higher levels, oxygen may be recommended if there are signs the heart is straining under the extra workload. Supplemental oxygen won’t reverse the disease, but it can ease breathlessness, reduce the heart’s burden, and improve your ability to stay active.
Exercise: Helpful but Needs Structure
For years, patients with pulmonary hypertension were told to avoid exercise. That advice has changed significantly. Supervised, carefully structured exercise programs improve exercise capacity, symptoms, and quality of life. The key word is “structured.” In well-studied programs, patients train at low workloads (stationary cycling at 10 to 60 watts, light dumbbell exercises with weights of about one to two pounds) with continuous monitoring of heart rate and oxygen saturation. Training intensity is kept at 60% to 80% of the maximum heart rate established during a supervised stress test, and oxygen levels must stay above 85%, with supplemental oxygen provided if saturation dips below 90%.
These programs typically include interval-style cycling, walking, light resistance work, and breathing exercises spread across the day rather than done in a single intense session. Starting under medical supervision is important because unsupervised high-intensity exercise in someone with significantly elevated pulmonary pressures can be dangerous.
Dietary and Fluid Management
Sodium restriction is one of the simplest and most impactful lifestyle changes. Excess sodium causes your body to retain fluid, which increases blood volume and puts additional strain on an already overworked right side of the heart. The American Heart Association recommends no more than 1,500 mg of sodium per day, roughly three-quarters of a teaspoon of salt. For context, a single fast-food meal can easily exceed that entire daily limit.
Fluid intake may also need to be limited, particularly if you’re retaining fluid despite diuretic use. Diuretics (water pills) are commonly prescribed alongside PAH-specific medications to manage swelling and fluid buildup, even though they don’t treat the underlying vascular disease. Maintaining a healthy weight, avoiding alcohol in excess, and staying up to date on flu and pneumonia vaccinations round out the lifestyle recommendations, since respiratory infections can trigger dangerous flare-ups.
Combination Therapy and Long-Term Outlook
The biggest shift in treatment philosophy over the past decade has been the move toward early, aggressive combination therapy. Rather than starting one drug, waiting, and adding another only if symptoms worsen, many specialists now start patients on two or even three drugs from different pathways right away. Registry data shows that over 73% of patients end up on combination therapy during follow-up, and this approach is linked to measurable improvements in risk scores and survival.
Regular follow-up is essential because the disease can progress even when you feel stable. Monitoring typically includes repeat echocardiograms, six-minute walk tests, blood markers of heart strain, and sometimes repeat catheterization. Treatment adjustments are common and expected. The goal is to keep you in the lowest possible risk category, where long-term outcomes are most favorable.